Recently, Baiyin Biotechnology, an innovative biomaterials R&D and application company, announced the completion of a pre-A round of financing of more than 100 million yuan, jointly led by Woyong Fund, Yunqi Capital and Fuhua Capital, and co-invested by Cornerstone Capital and Yayi Capital. After the completion of this round of financing, Baiyin Biotech will further strengthen the upgrade of R&D platform and capacity expansion.

Faye Wong, Danlin Yu and Chaomei Wu of AnJie Broad & Bright’s Shanghai office provided full legal services for the financing.

Founded in 2021, Biotech uses synthetic biology and machine learning (BT-IT) technology to drive bio-based materials and product development. The core team includes a number of doctors with the world’s top academic achievements and experienced senior experts in the field of process engineering, mainly laying out the development pipeline of protein and polysaccharide raw materials, and related raw materials and products are widely used in medicine, medical beauty, cosmetics, food and other fields.